Table Info

Table 1.

Allele frequencies of 1-97981199-T-TA and 1-97981622-G-GA across African ancestry populations

Population	1-97981199-T-TA*	1-97981622-G-GA*
African Caribbean in Barbados	18.2%	18.2%
African Ancestry in Southwest US	18.0%	18.0%
Esan in Nigeria	16.2%	16.2%
Gambian in Western Division, The Gambia	26.5%	26.1%
Luhya in Webuye, Kenya	15.7%	15.7%
Mende in Sierra Leone	17.6%	17.6%
Yoruba in Ibadan, Nigeria	17.1%	16.7%

* Allele frequencies (%) obtained from 1000 Genomes Project

Declarations

Author contributions

AM: Conceptualization, Data curation, Methodology, Visualization, Writing—original draft, Writing—review & editing. SC: Investigation, Methodology. GDA: Data curation, Formal analysis, Investigation, Methodology. VD: Resources. AI: Supervision, Writing—review & editing. MC: Conceptualization, Project administration, Supervision, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The review of this case report by the Ethics Committee was waived as it aligns with the Italian Association of Medical Oncology (AIOM) guidelines, contributes new or unusual findings to the medical community, enhancing awareness and encouraging advancements in medical knowledge and practice. Moreover, the study complies with the Declaration of Helsinki’s ethical principles.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

5-Fluorouracil (i.v.), capecitabine and tegafur containing products: pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity [Internet]. [Cited 2023 Nov 6]. Available from: https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-5-fluorouracil-iv-capecitabine-and-tegafur-containing-products-pre-treatment-testing-identify-dpd-deficient-patients-increased-risk-severe-toxicity_en.pdf

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19:1459–67. [DOI] [PubMed]

Raida M, Schwabe W, Häusler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5’-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res. 2001;7:2832–9. [PubMed]

Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P, et al. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. Pharmacogenomics J. 2016;16:320–5. [DOI] [PubMed]

Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen JJ, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16:1277–86. [DOI] [PubMed]

Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015;137:2971–80. [DOI] [PubMed]

Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14:1255–72. [DOI] [PubMed]

Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031–9. [DOI] [PubMed] [PMC]

Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist. 2021;26:1008–16. [DOI] [PubMed] [PMC]

10.

EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine [Internet]. European Medicines Agency; c2020 [cited 2023 Nov 6]. Available from: https://www.ema.europa.eu/en/documents/referral/fluorouracil-and-fluorouracil-related-substances-article-31-referral-ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-and-flucytosine_en.pdf

11.

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103:210–6. [DOI] [PubMed] [PMC]

12.

Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28:508–17. [DOI] [PubMed] [PMC]

13.

Hamzic S, Aebi S, Joerger M, Montemurro M, Ansari M, Amstutz U, et al. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and personalised therapy. Swiss Med Wkly. 2020;150:w20375. [DOI] [PubMed]

14.

Vreken P, Van Kuilenburg AB, Meinsma R, Smit GP, Bakker HD, De Abreu RA, et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherit Metab Dis. 1996;19:645–54. [DOI] [PubMed]

15.

Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013;108:2505–15. [DOI] [PubMed] [PMC]

16.

Kim W, Cho YA, Kim DC, Lee KE. Elevated risk of fluoropyrimidine-associated toxicity in European patients with DPYD genetic polymorphism: a systematic review and meta-analysis. J Pers Med. 2022;12:225. [DOI] [PubMed] [PMC]

17.

Coenen MJH, Paulussen ADC, Breuer M, Lindhout M, Tserpelis DCJ, Steyls A, et al. Evolution of dihydropyrimidine dehydrogenase diagnostic testing in a single center during an 8-year period of time. Curr Ther Res Clin Exp. 2018;90:1–7. [DOI] [PubMed] [PMC]

18.

Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414–7. [DOI] [PubMed] [PMC]

19.

Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110:563–72. [DOI] [PubMed] [PMC]

20.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303. [DOI] [PubMed] [PMC]

21.

Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. [DOI] [PubMed] [PMC]

22.

Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94:640–5. [DOI] [PubMed] [PMC]

23.

Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81:47–51. [DOI] [PubMed] [PMC]

24.

Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007;249:271–82. [DOI] [PubMed]

25.

Worldwide cancer data [Internet]. WCRF International; [cited 2023 Nov 6]. Available from: https://www.wcrf.org/cancer-trends/worldwide-cancer-data/

26.

Gmeiner WH. A narrative review of genetic factors affecting fluoropyrimidine toxicity. Precis Cancer Med. 2021;4:38. [DOI] [PubMed] [PMC]

27.

Wörmann B, Bokemeyer C, Burmeister T, Köhne CH, Schwab M, Arnold D, et al. Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper. Oncol Res Treat. 2020;43:628–36. [DOI] [PubMed]